Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCA00186 in Advanced Solid Tumors
NCT04989387Phase 1Terminated
- Sponsor
- Incyte
- Start
- Oct 2021
- Primary completion
- Sep 2024
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Therapeutic Vaccines
- Countries
- 6
01
Overview
Phase 1, open-label trial of inca00186 in solid tumor (advanced stage), squamous cell carcinoma of the head and neck (HNSCC), colorectal cancer (CRC) and 5 more (4 arms), sponsored by Incyte. Primary endpoints: Number of participants with adverse events and withdrawal due to AEs up to 27 months, Dose-Limiting Toxicity up to 27 months and 1 more. Started Oct 2021; status: terminated.
02
Drugs
inca00186
03
Conditions
solid tumor (advanced stage)squamous cell carcinoma of the head and neck (HNSCC)colorectal cancer (CRC)gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT04989387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04989387.